{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:43:07Z","timestamp":1793374987343,"version":"4.5.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","funder":[{"name":"Gruppo Italiano Ricerca Cancro Gastrico - GIRCG"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The prognostic significance of microsatellite instability (MSI) and HER2 status in advanced gastric cancer (AGC) treated with neoadjuvant or conversion chemotherapy (NAC) remains unclear. This study aimed to evaluate their impact on pathological response and survival outcomes in AGC patients undergoing NAC followed by surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center, retrospective observational study included 121 patients with gastric adenocarcinoma at clinical stage &gt;cT2N0, defined as tumor invasion beyond the muscularis propria, nodal involvement, or both. Eligible patients received at least two cycles of NAC and underwent surgical resection. Adults without other malignancies and with biopsy samples available for molecular analysis were included. Data were obtained from a prospectively maintained surgical database. Imaging studies were reviewed by expert radiologists, and molecular analyses were performed in the pathology department.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 121 patients, MSI was identified in 6.6% and HER2 positivity in 9.9%. All MSI tumors were HER2 negative (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.001). HER2 positivity was more frequent in intestinal-type tumors (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.034) and was associated with better pathological response (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.048). The 5-year overall survival (OS) rate was 44.7%, with a median OS of 42.6 months. Multivariate Cox regression identified tumor location in the upper third, residual tumor, nodal stage, Lauren diffuse-mixed histotype, and negative HER2 status as independent prognostic factors (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.05). MSI status was not significantly associated with OS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.786), although a trend toward improved survival was observed in MSI-H patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HER2 overexpression correlated with better pathological response and independently predicted improved OS. MSI and HER2 status may serve as biomarkers to guide preoperative treatment strategies in AGC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cej.0000000000000982","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T13:00:08Z","timestamp":1751374808000},"page":"66-77","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Impact of HER2 and microsatellite instability status on response to neoadjuvant\/conversion therapy and survival in patients with gastric cancer"],"prefix":"10.1097","volume":"35","author":[{"given":"Stefania Angela","family":"Piccioni","sequence":"first","affiliation":[{"name":"Unit of General Surgery and Surgical Oncology, Department of Oncology, University Hospital of Siena"},{"name":"Department of Medicine, Surgery and Neurosciences, University of Siena"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Costantini","sequence":"additional","affiliation":[{"name":"Unit of Pathological Anatomy, Department of Cellular Therapies, Hematology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Petrioli","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology, Department of Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Bagnacci","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Neurosciences, University of Siena"},{"name":"Unit of Diagnostic Imaging, University Hospital of Siena, Siena"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Ferrara","sequence":"additional","affiliation":[{"name":"Unit of Pathological Anatomy, Department of Cellular Therapies, Hematology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Andreucci","sequence":"additional","affiliation":[{"name":"Unit of General Surgery and Surgical Oncology, Department of Oncology, University Hospital of Siena"},{"name":"Department of Medicine, Surgery and Neurosciences, University of Siena"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovico","family":"Carbone","sequence":"additional","affiliation":[{"name":"Unit of General Surgery and Surgical Oncology, Department of Oncology, University Hospital of Siena"},{"name":"Department of Medicine, Surgery and Neurosciences, University of Siena"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ongaro","sequence":"additional","affiliation":[{"name":"Unit of General Surgery, Policlinico Abano, Abano Terme (PD)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natale","family":"Calomino","sequence":"additional","affiliation":[{"name":"Unit of General Surgery and Kidney Transplantation, Department of Surgical Sciences, University Hospital of Siena, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Sandini","sequence":"additional","affiliation":[{"name":"Unit of General Surgery and Surgical Oncology, Department of Oncology, University Hospital of Siena"},{"name":"Department of Medicine, Surgery and Neurosciences, University of Siena"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Mazzei","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Neurosciences, University of Siena"},{"name":"Unit of Diagnostic Imaging, University Hospital of Siena, Siena"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Roviello","sequence":"additional","affiliation":[{"name":"Unit of General Surgery and Surgical Oncology, Department of Oncology, University Hospital of Siena"},{"name":"Department of Medicine, Surgery and Neurosciences, University of Siena"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Marrelli","sequence":"additional","affiliation":[{"name":"Unit of General Surgery and Surgical Oncology, Department of Oncology, University Hospital of Siena"},{"name":"Department of Medicine, Surgery and Neurosciences, University of Siena"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"R1-20251211","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.3748\/wjg.v22.i19.4619","article-title":"HER2 testing in gastric cancer: an update.","volume":"22","author":"Abrahao-Machado","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R2-20251211","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction denocarcinoma (FLOT4): a randomised, phase 2\/3 trial.","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet (London, England)"},{"key":"R3-20251211","doi-asserted-by":"crossref","first-page":"S899","DOI":"10.1016\/j.annonc.2020.08.1927","article-title":"1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma.","volume":"31","author":"Al-Batran","year":"2020","journal-title":"Ann Oncol"},{"key":"R4-20251211","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"R5-20251211","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma.","volume":"513","author":"Bass","year":"2014","journal-title":"Nature"},{"key":"R6-20251211","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.5858\/arpa.2013-0691-RA","article-title":"A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: how well do you know your FFPE specimen?","volume":"138","author":"Bass","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"R7-20251211","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy.","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"key":"R8-20251211","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/jso.26657","article-title":"Impact of neoadjuvant therapy followed by laparoscopic radical gastrectomy with D2 lymph node dissection in Western population: a multi\u2010institutional propensity score\u2010matched study.","volume":"124","author":"Bracale","year":"2021","journal-title":"J Surg Oncol"},{"key":"R9-20251211","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.3390\/molecules25081864","article-title":"Use of Fluorescence In Situ Hybridization (FISH) in Diagnosis and Tailored Therapies in Solid Tumors.","volume":"25","author":"Chrzanowska","year":"2020","journal-title":"Molecules"},{"key":"R10-20251211","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The clavien-dindo classification of surgical complications.","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann Surg"},{"key":"R11-20251211","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nm.3850","article-title":"Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.","volume":"21","author":"Cristescu","year":"2015","journal-title":"Nat Med"},{"key":"R12-20251211","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"R13-20251211","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s10120-016-0615-3","article-title":"The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015.","volume":"20","author":"De Manzoni","year":"2017","journal-title":"Gastric Cancer"},{"key":"R14-20251211","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1186\/s12885-021-08768-7","article-title":"Results of the observational prospective RealFLOT study.","volume":"21","author":"Giommoni","year":"2021","journal-title":"BMC Cancer"},{"key":"R15-20251211","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.3748\/wjg.v19.i14.2171","article-title":"Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.","volume":"19","author":"He","year":"2013","journal-title":"World J Gastroenterol"},{"key":"R16-20251211","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7150\/jca.4090","article-title":"HER2 as a prognostic marker in gastric cancer - a systematic analysis of data from the literature.","volume":"3","author":"J\u00f8rgensen","year":"2012","journal-title":"J Cancer"},{"key":"R17-20251211","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"R18-20251211","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3390\/curroncol30010067","article-title":"Extended lymphadenectomy for gastric cancer in the neoadjuvant era: current status, clinical implications and contentious issues.","volume":"30","author":"Marano","year":"2023","journal-title":"Current Oncology (Toronto, Ont.)"},{"key":"R19-20251211","doi-asserted-by":"crossref","first-page":"7954","DOI":"10.3748\/wjg.v21.i26.7954","article-title":"Multimodal treatment of gastric cancer in the West: where are we going?","volume":"21","author":"Marrelli","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R20-20251211","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1245\/s10434-015-4931-3","article-title":"Strong prognostic value of microsatellite instability in intestinal type non-cardia gastric cancer.","volume":"23","author":"Marrelli","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"R21-20251211","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3390\/cancers16071376","article-title":"Posterior and para-aortic (d2plus) lymphadenectomy after neoadjuvant\/conversion therapy for locally advanced\/oligometastatic gastric cancer.","volume":"16","author":"Marrelli","year":"2024","journal-title":"Cancers"},{"key":"R22-20251211","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1007\/s00330-021-08205-0","article-title":"Structured and shared CT radiological report of gastric cancer: a consensus proposal by the Italian Research Group for Gastric Cancer (GIRCG) and the Italian Society of Medical and Interventional Radiology (SIRM).","volume":"32","author":"Mazzei","year":"2022","journal-title":"Eur Radiol"},{"key":"R23-20251211","doi-asserted-by":"crossref","first-page":"107275","DOI":"10.1016\/j.ejso.2023.107275","article-title":"A pragmatic approach improves the clinical management of stage IV gastric cancer: Comparison between the Meta-Gastro results and the GIRCG\u2019s retrospective series.","volume":"50","author":"Ministrini","year":"2024","journal-title":"Eur J Surg Oncol"},{"key":"R24-20251211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/781742","article-title":"The postoperative component of MAGIC chemotherapy is associated with improved prognosis following surgical resection in gastric and gastrooesophageal junction adenocarcinomas.","volume":"2013","author":"Mirza","year":"2013","journal-title":"Int J Surgical Oncol"},{"key":"R25-20251211","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.3390\/cancers12102790","article-title":"Preoperative or perioperative docetaxel, oxaliplatin, and capecitabine (GASTRODOC regimen) in patients with locally-advanced resectable gastric cancer: a randomized phase-II trial.","volume":"12","author":"Monti","year":"2020","journal-title":"Cancers"},{"key":"R26-20251211","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9<1894::AID-CNCR3>3.0.CO;2-J","article-title":"The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas.","volume":"85","author":"Nakajima","year":"1999","journal-title":"Cancer"},{"key":"R27-20251211","doi-asserted-by":"crossref","first-page":"6601","DOI":"10.1007\/s00432-023-04636-y","article-title":"Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO study.","volume":"149","author":"Nappo","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"R28-20251211","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1200\/JCO.19.01124","article-title":"Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer.","volume":"37","author":"Pietrantonio","year":"2019","journal-title":"J Clin Oncol"},{"key":"R29-20251211","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/bjs.10663","article-title":"Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer.","volume":"105","author":"Polom","year":"2018","journal-title":"Br J Surg"},{"key":"R30-20251211","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.3390\/cancers13112839","article-title":"TremelImumab and durvalumab combination for the non-operative management (NOM) of Microsatellite INSTABILITY (MSI)-high resectable gastric or gastroesophageal junction cancer: the multicentre, single-arm, multi-cohort, phase II INFINITY study.","volume":"13","author":"Raimondi","year":"2021","journal-title":"Cancers"},{"key":"R31-20251211","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/978-1-4939-8935-5_22","article-title":"Making formalin-fixed, paraffin embedded blocks.","volume":"1897","author":"Sadeghipour","year":"2019","journal-title":"Methods Mol Biol"},{"key":"R32-20251211","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1 - update and clarification: from the RECIST committee.","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"R33-20251211","doi-asserted-by":"crossref","first-page":"102226","DOI":"10.1016\/j.esmoop.2023.102226","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer.","volume":"9","author":"Shitara","year":"2024","journal-title":"ESMO Open"},{"key":"R34-20251211","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaoncol.2016.6762","article-title":"Mismatch repair deficiency, microsatellite instability, and survival.","volume":"3","author":"Smyth","year":"2017","journal-title":"JAMA Oncology"},{"key":"R35-20251211","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s10120-019-00968-2","article-title":"Conversion gastrectomy for stage IV unresectable gastric cancer: a GIRCG retrospective cohort study.","volume":"22","author":"Solaini","year":"2019","journal-title":"Gastric Cancer"},{"key":"R36-20251211","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.gie.2019.03.022","article-title":"A survival guide to HER2 testing in gastric\/gastroesophageal junction carcinoma.","volume":"90","author":"Subasinghe","year":"2019","journal-title":"Gastrointest Endosc"},{"key":"R37-20251211","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R38-20251211","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.5858\/arpa.2010-0541-OA","article-title":"Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.","volume":"135","author":"Tafe","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"R39-20251211","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/annonc\/mdi064","article-title":"Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II\u03b1 gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.","volume":"16","author":"Tanner","year":"2005","journal-title":"Ann Oncol"},{"key":"R40-20251211","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update.","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"R41-20251211","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3892\/ol.2023.14081","article-title":"Concordance between microsatellite instability testing and immunohistochemistry for mismatch repair proteins and efficient screening of mismatch repair deficient gastric cancer.","volume":"26","author":"Yamamoto","year":"2023","journal-title":"Oncol Lett"},{"key":"R42-20251211","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"key":"R43-20251211","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10120-015-0575-z","article-title":"Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification.","volume":"19","author":"Yoshida","year":"2016","journal-title":"Gastric Cancer"},{"key":"R44-20251211","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3892\/mco.2015.506","article-title":"Microsatellite instability and survival in gastric cancer: a systematic review and meta-analysis.","volume":"3","author":"Zhu","year":"2015","journal-title":"Mol Clin Oncol"},{"key":"R45-20251211","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.3390\/cancers14092204","article-title":"Microsatellite status detection in gastrointestinal cancers: PCR\/NGS is mandatory in negative\/patchy MMR immunohistochemistry.","volume":"14","author":"Zito Marino","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000982","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T14:00:15Z","timestamp":1765461615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000982","relation":{},"ISSN":["0959-8278","1473-5709"],"issn-type":[{"value":"0959-8278","type":"print"},{"value":"1473-5709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]}}}